Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 525-530

  Lepor, Herbert ^a   Kaplan, Steven A ^a   Klimberg, Ira ^a   Mobley, David F ^a   Fawzy, Ahmed ^a   Gaffney, Michael ^a   Ice, Kathleen ^a   Dias, Norma ^a  

^a NONE

Author keywords

adrenergic alpha receptor blockaders; doxazosin; hypertension; prostate; prostatic hypertrophy

Indexed keywords

DOXAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TREATMENT PLANNING; VERTIGO;

EID: 0031021415     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65193-0     Document Type: Article

References (27)

1. Garraway, W. M., Collins, G. N. and Lee, R. J.: High prevalence of benign prostatic hypertrophy in the community. Lancet, 338: 469, 1991.
2. Garraway, W. M., Russell, E. B. A. W., Lee, R. J., Collins, G. N., McKelvie, G. B., Hehir, M., Rogers, A. C. N. and Simpson, R. J.: Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Brit. J. Gen. Pract., 43: 318, 1993.
3. McConnell, J. D., Barry, M. J., Bruskewitz, R. C., Bueschen, A. J., Denton, S. E., Holtgrewe, H. L., Lange, J., McClennan, B. L., Mebust, W. K., Reilly, N. J., Roberts, R. G., Sacks, S. A. and Wasson, J. H.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. Rockville, Maryland: United States Department of Health and Human Services, 1994.
4. Jønler, M., Riehmann, M. and Bruskewitz, R. C.: Benign prostatic hyperplasia. Current pharmacological treatment. Drugs, 47: 66, 1994.
5. Poulter, N. R.: Risk factors for cardiovascular disease: "clustering" in the older hypertensive man. Brit. J. Clin. Pract., suppl., 74: 4, 1994.
6. Boyle, P.: Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension. Brit. J. Clin. Pract., suppl., 74: 18, 1994.
7. Young, R. A. and Brogden, R. N.: Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild to moderate hypertension. Drugs, 35: 525, 1988.
8. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med., 153: 154, 1993.
9. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Sub-Committee and the 1993 Guidelines for the Management of Mild Hypertension. J. Hypertens., 11: 905, 1993.
10. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
11. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol., 154: 110, 1995.
12. Holme, J. B., Christensen, M. M., Rasmussen, P. C., Jacobsen, F., Nielsen, J., Nørgaard, J. P., Olesen, S., Noer, I., Wolf, H. and Husted, S. E.: 29 Weeks of doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand. J. Urol., 28: 77, 1994.
13. Janknegt, R. A. and Chapple, C. R.: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur. Urol., 24: 319, 1993.
14. Kirby, R. S., Chapple, C. R. and Christmas, T. J.: Doxazosin: minimal blood pressure effects in normotensive BPH patients. J. Urol., part 2, 149: 434A, abstract 886, 1993.
15. Kirby, R. S.: Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. Brit. J. Clin. Pract., suppl., 74: 23, 1994.
16. Barry, M. J., Fowler, F. J., Jr., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K. and the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol., 148: 1549, 1992.
17. Boyarsky, S., Jones, G., Paulson, D. F. and Prout, G. R., Jr.: A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans. Amer. Ass. Genito-Urin. Surg., 68: 29, 1977.
18. Lepor, H.: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology, 45: 406, 1995.
19. Lepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G. and Madsen, P.: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol., 148: 1467, 1992.
20. DiSilverio, F.: Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Brit. J. Urol., suppl., 70: 22, 1992.
21. Lloyd, S. N., Buckley, J. F., Chilton, C. P., Ibrahim, I., Kaisary, A. V. and Kirk, D.: Terazosin in the treatment of benign prostatic hyperplasia: a multicenter, placebo-controlled trial. Brit. J. Urol., suppl., 70: 17, 1992.
22. Jardin, A., Bensadoun, H., Delauche-Cavalier, M. C. and Attali, P.: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet, 337: 1457, 1991.
23. Carbin, B. E., Bauer, P., Friskand, M. and Moyse, D.: Efficacy of alfuzosine in benign hyperplasia of the prostate. Scand. J. Urol. Nephrol., 138: 73, 1991.
24. Teillac, P., DeLauche-Cavallier, M. C., Attali, P. and the DUALF Group: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Brit. J. Urol., 70: 58, 1992.
25. Kawabe, K., Ueno, A., Takimoto, Y., Aso, Y. and Kato, H.: Use of an alpha-1 blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol., 144: 908, 1990.
26. Landsberg, L.: Unique problems in the treatment of the older hypertensive male. Introduction: increased sympathetic nervous system activity in the elderly. Brit. J. Clin. Pract., suppl., 74: 1, 1994.
27. Furuya, S., Kumamoto, Y., Yokoyama, E., Tsukamoto, T., Izumi, T. and Abiko, Y.: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol., 128: 836, 1982.